» Articles » PMID: 34691328

Change in Invasively Measured Mean Pulmonary Artery Pressure After Transcatheter Mitral Valve Repair Is Associated With Heart Failure Readmission

Overview
Journal Cardiol Res
Date 2021 Oct 25
PMID 34691328
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pre-existing pulmonary hypertension is associated with poor outcomes after transcatheter mitral valve repair (TMVr) for mitral regurgitation (MR). However, the impact of an immediate change in mean pulmonary artery pressure (ΔmPAP) following TMVr on outcomes is unknown.

Methods: Patients who underwent TMVr from December 2015 to February 18, 2020 at our institution for symptomatic 3-4+ MR and who had invasive hemodynamics measured immediately pre- and post-TMVR were included. Multivariate Cox regression analysis was performed to examine the association of ΔmPAP (post-TMVr - pre-TMVr mPAP) with the primary endpoint of heart failure (HF) readmission at 1 year. Secondary endpoints included all-cause mortality and the composite endpoint of HF readmission or all-cause mortality at 1 year.

Results: Among 55 patients, 55% were men, mean age was 72 ± 14.2 years, and mean ΔmPAP was -1.4 ± 8.2 mm Hg. Overall, HF readmission occurred in 14 (25%), death in 10 (18%), and the composite endpoint in 20 (36%) patients. In multivariable analyses, higher ΔmPAP was significantly associated with HF readmission (hazard ratio (HR) = 1.10, 95% confidence interval (CI): 1.00 - 1.21; P = 0.04). ΔmPAP was not associated with death (HR = 1.04, 95% CI: 0.96 - 1.14; P = 0.33), though there was a numerical but statistically non-significant trend towards the composite endpoint (HR = 1.06, 95% CI: 1.00 - 1.13; P = 0.06) driven by HF readmission.

Conclusion: Higher ΔmPAP immediately following TMVr was associated with increased HF readmission at 1 year. Larger prospective studies are needed to validate these data and further explore the utility of ΔmPAP as a novel hemodynamic parameter to predict post-TMVR outcomes.

Citing Articles

The impact of pulmonary hypertension on prognosis in moderate-to-severe mitral regurgitation patients treated with transcatheter edge-to-edge mitral valve repair: a comprehensive meta-analysis.

Wei Z, Shao X, An Z, Chang Y, Liu S, Luo Z Front Cardiovasc Med. 2025; 11:1489674.

PMID: 39866800 PMC: 11757250. DOI: 10.3389/fcvm.2024.1489674.


Impact of pulmonary hypertension on outcomes after TEER in patients suffering from mitral regurgitation.

Jaeger P, Toskas I, Henes J, Shcherbyna S, Schwarz F, Euper M Clin Res Cardiol. 2024; 114(2):203-214.

PMID: 38565712 PMC: 11839688. DOI: 10.1007/s00392-024-02442-1.

References
1.
Maor E, Raphael C, Panaich S, Reeder G, Nishimura R, Nkomo V . Acute Changes in Left Atrial Pressure After MitraClip Are Associated With Improvement in 6-Minute Walk Distance. Circ Cardiovasc Interv. 2017; 10(4). DOI: 10.1161/CIRCINTERVENTIONS.116.004856. View

2.
Al-Bawardy R, Vemulapalli S, Thourani V, Mack M, Dai D, Stebbins A . Association of Pulmonary Hypertension With Clinical Outcomes of Transcatheter Mitral Valve Repair. JAMA Cardiol. 2019; 5(1):47-56. PMC: 6902209. DOI: 10.1001/jamacardio.2019.4428. View

3.
Vachiery J, Adir Y, Barbera J, Champion H, Coghlan J, Cottin V . Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol. 2013; 62(25 Suppl):D100-8. DOI: 10.1016/j.jacc.2013.10.033. View

4.
Feldman T, Foster E, Glower D, Glower D, Kar S, Rinaldi M . Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011; 364(15):1395-406. DOI: 10.1056/NEJMoa1009355. View

5.
Kar S, Feldman T, Qasim A, Trento A, Kapadia S, Pedersen W . Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients. Heart. 2018; 105(21):1622-1628. DOI: 10.1136/heartjnl-2017-312605. View